Concentrations of protease inhibitors in cord blood after in utero exposure
Department of Pediatrics
Adult; Double-Blind Method; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; effects; Humans; Infant, Newborn; *Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications, Infectious
Immunology and Infectious Disease | Pediatrics
OBJECTIVE: To determine the concentrations of protease inhibitors in cord blood after prenatal protease inhibitor use by pregnant women.
DESIGN: Retrospective analysis of samples collected in a clinical trial.
METHODS: Protease inhibitor concentrations were measured in cord blood samples collected from women enrolling in the PACTG 316 study who were receiving prenatal protease inhibitor antiretroviral therapy.
RESULTS: In cord blood samples from 68 women treated with protease inhibitors during pregnancy, the concentration of these drugs was below the assay lower limit of detection in most samples, including all samples from women receiving indinavir (n = 21) and saquinavir (n = 8), 5 of 6 samples (83%) from women receiving ritonavir and 24 of 38 samples (63%) from women receiving nelfinavir.
CONCLUSIONS: Low protease inhibitor concentrations in the fetus decrease the likelihood of teratogenic and toxic effects of these drugs but could fail to provide protection from transplacental or intrapartum transmission of HIV-1.
Pediatr Infect Dis J. 2002 Sep;21(9):835-8. Link to article on publisher's site
The Pediatric infectious disease journal
Mirochnick M, Dorenbaum A, Holland D, Cunningham-Scharder B, Cunningham CK, Gelber RD, Mofenson LM, Culnane M, Connor JD, Sullivan JL. (2002). Concentrations of protease inhibitors in cord blood after in utero exposure. Immunology/Infectious Disease. Retrieved from https://escholarship.umassmed.edu/peds_immunology/25